Skip to main content

Table 3 Mean cost by year and patient age at diagnosis

From: Real world costs and cost-effectiveness of Rituximab for diffuse large B-cell lymphoma patients: a population-based analysis

Mean cost (CAD$)

Year from diagnosis

 

1

2

3

4

5

All Ages

    
 

CHOP

45089

10890

5415

4052

3549

 

RCHOP

63266

7733

5816

4343

4135

<60 yrs old

    
 

CHOP

44401

12249

5211

3633

2787

 

RCHOP

60007

7031

5084

2825

2507

60-79 yrs old

    
 

CHOP

46488

9678

6161

4926

4752

 

RCHOP

67364

8532

6254

4894

3774

≥80 yrs old

    
 

CHOP

41490

6902

1988

1699

2034

 

RCHOP

64310

8465

7681

8142

5533

  1. All values discounted (at r = 3%) and censored adjusted (with Inverse Probability Weighting). All costs are in 2009 Canadian dollars.
  2. CHOP, cyclophosphamide, doxorubicin, vincristine, and prednisone; RCHOP, CHOP with rituximab.